First in Human Study of TUB-030 in Patients with Advanced Solid Tumors

Sponsor: Tubulis GmbH

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06657222

Patient View

This trial evaluates the safety and efficacy of TUB-030 in adults with advanced solid tumors. Participants receive TUB-030 IV every 3 weeks. Eligibility includes adequate organ function, stable brain metastases, and measurable disease. Women of childbearing potential must use contraception. The study aims to establish the maximum tolerated dose and assess effectiveness in specific cancer types.

Patient Parameters

Program Overview

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are:

To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose.

Participants will:

Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

Eligibility Criteria

Inclusion Criteria

  1. Male or non-pregnant, non-breastfeeding female aged 18 years or older
  2. Adequate organ function
  3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had their last dose at least 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter, before C1D1
  4. AEs related to prior therapy, radiotherapy or surgical procedures must resolve to ≤grade 1.
  5. For patients with known brain metastases, evidence of clinically stable disease post radiation therapy is required prior to enrollment.
  6. For patients who underwent radiotherapy (≥ 30% of the bone marrow or wide field) to sites outside the brain, the final dose of radiation must have been administered ≥ 28 days prior to C1D1. For patients who underwent palliative radiotherapy (≤ 30% of the bone marrow or wide field) the final dose of radiation must have been administered ≥14 days prior to C1D1.
  7. Radiologically measurable disease by RECIST v1.1, 4 weeks before C1D1, that can include a lesion in an irradiated field that shows progression according to RECIST v1.1 after irradiation.
  8. Eastern Cooperative Oncology Group (ECOG) 0-1.
  9. Have a life expectancy of >12 weeks for disease-related mortality, as evaluated by the INV.
  10. In the opinion of the INV, the patient must be able and willing to understand and give signed informed consent
  11. Women of childbearing potential (WOCBP) who are sexually active with a non-sterilized partner must use at least 1 highly effective method of contraception (with a failure rate of 1% per year) from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of patients of childbearing potential Patients must agree to continue a highly effective contraceptive method, refrain from egg cell donation and breastfeeding while on study treatment and for 5 half-lives plus 6 months after the last dose of study treatment.

Exclusion Criteria

Get This Program In Your Inbox

You can sign up and apply your patients for this program.